2192 — Medlive Technology Co Share Price
Last trade - 00:00- HK$6.91bn
- HK$2.12bn
- CNY314.05m
- 53
- 28
- 73
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 38.42 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -16.77% | ||
| Dividend Yield (f) | 1.59% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.37 | ||
| Price to Tang. Book | 1.43 | ||
| Price to Free Cashflow | 91.89 | ||
| Price to Sales | 17.75 | ||
| EV to EBITDA | 23.11 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.38% | ||
| Return on Equity | 4.31% | ||
| Operating Margin | 57.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 83.46 | 121.57 | 213.53 | 284.44 | 314.05 | 395.25 | 494.11 | 39.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +120.38 | +170.34 | -24.34 | +70.96 | +77.47 | -21.35 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medlive Technology Co Ltd is a China-based investment holding company mainly operates online professional physician platform. The Company mainly operates three segments. Its Precision Marketing and Corporate Solutions segment provides precision marketing solutions and corporate solutions. Its precision marketing solutions include digital detailing, digital marketing consulting and digital content creation services. Its revenue of its corporate solutions is primarily software as a service (SaaS). The Medical Knowledge Solutions segment mainly provides professional medical information and medical software services. The Intelligent Patient Management Solutions segment mainly provides online patient consultation and prescription services and patient management services. The Company mainly conducts its business within domestic market.
Directors
- Liping Tian CHM (54)
- Lijun Tian VPR (47)
- Xin Zhou VPR (40)
- Jiangtao Xin VPR (44)
- Liancheng Yang VPR (42)
- Lixin Tian EDR (52)
- Juan Liu OTH (37)
- Jiang Nan OTH (33)
- Kar Yee Szeto SEC
- Yanling Yang SEC
- Zhuolin Li NED (38)
- Eiji Tsuchiya NED (56)
- Jun Ma NID (66)
- Shan Wang NID (47)
- Richard Yeh NID (52)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- April 8th, 2013
- Public Since
- July 15th, 2021
- No. of Employees
- 668
- Sector
- Media & Publishing
- Industry
- Consumer Cyclicals
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 727,062,500
- Address
- Ugland House, BEIJING, KY1-1104
- Web
- https://www.medlive.cn/
- Phone
- Auditors
- Ernst & Young
Upcoming Events for 2192
Similar to 2192
Activation group
Stock Exchange of Hong Kong Limited
Adtiger Corporations
Stock Exchange of Hong Kong Limited
Alibaba Pictures
Stock Exchange of Hong Kong Limited
A Metaverse Co
Stock Exchange of Hong Kong Limited
Asiaray Media
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 18:14 UTC, shares in Medlive Technology Co are trading at HK$9.50. This share price information is delayed by 15 minutes.
Shares in Medlive Technology Co last closed at HK$9.50 and the price had moved by +1.06% over the past 365 days. In terms of relative price strength the Medlive Technology Co share price has outperformed the FTSE Developed Asia Pacific Index by +5.05% over the past year.
The overall consensus recommendation for Medlive Technology Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Medlive Technology Co dividend yield is 2% based on the trailing twelve month period.
Last year, Medlive Technology Co paid a total dividend of CNY0.17, and it currently has a trailing dividend yield of 2%.Looking ahead, the next dividend pay date is 2023-12-04.
We do not have data on when Medlive Technology Co is to next pay dividends. The historic dividend yield on Medlive Technology Co shares is currently 2%.
To buy shares in Medlive Technology Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$9.50, shares in Medlive Technology Co had a market capitalisation of HK$6.91bn.
Here are the trading details for Medlive Technology Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2192
Based on an overall assessment of its quality, value and momentum Medlive Technology Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Medlive Technology Co is HK$11.06. That is 16.44% above the last closing price of HK$9.50.
Analysts covering Medlive Technology Co currently have a consensus Earnings Per Share (EPS) forecast of CNY0.28 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medlive Technology Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +35.64%.
As of the last closing price of HK$9.50, shares in Medlive Technology Co were trading +14.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medlive Technology Co PE ratio based on its reported earnings over the past 12 months is 38.42. The shares last closed at HK$9.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Medlive Technology Co's management team is headed by:
- Liping Tian - CHM
- Lijun Tian - VPR
- Xin Zhou - VPR
- Jiangtao Xin - VPR
- Liancheng Yang - VPR
- Lixin Tian - EDR
- Juan Liu - OTH
- Jiang Nan - OTH
- Kar Yee Szeto - SEC
- Yanling Yang - SEC
- Zhuolin Li - NED
- Eiji Tsuchiya - NED
- Jun Ma - NID
- Shan Wang - NID
- Richard Yeh - NID